Dual HER2 Blockade and AI for HER2+/HR+ Advanced Breast Cancer

Treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor (HR)-positive advanced breast cancer is challenging because bidirectional cross talk between the estrogen receptor and HER2 can lead to the development of resistance to both hormonal and anti-HER2 therapy. In these patients, adding anti-HER2 to aromatase inhibitor (AI) therapy demonstrated improved […]

Read More

PET May Predict Long-Term Benefit With Anti-PD-1 Therapy in Melanoma

PD-1 targeting immune checkpoint inhibitors have revolutionized treatment of metastatic melanoma, resulting in long-term survival in many patients. However, there are few reliable predictors of long-term response to anti-PD-1 therapy in these patients. Currently, complete response (CR) by computed tomography (CT) imaging is considered the best indicator for long-term outcomes, and it appears that these […]

Read More

Nivolumab ± Ipilimumab Effective for Refractory Esophagogastric Cancer

There are few therapeutic options for patients with metastatic chemotherapy refractory esophagogastric cancer, and prognosis for these patients is poor. Immunotherapy with PD-1 targeting immune checkpoint inhibitors has been shown to be a highly effective treatment option across a variety of solid tumors. Preclinical and early clinical data support the role for immune checkpoint blockade […]

Read More

Talazoparib Outperforms Chemotherapy in BRCA+ Advanced Breast Cancer

For patients with advanced breast cancer who carry a germline mutation in BRCA1 or BRCA2, and are thus deficient in the repair mechanism for DNA double-strand breaks, treatment with a poly(adenosine diphosphase) polymerase (PARP) inhibitor is a highly effective therapeutic option. Talazoparib is a novel, highly potent PARP inhibitor that demonstrated promising responses among pretreated […]

Read More

EMA Positive Opinions in July For New Anticancer Therapies in Europe

On 26 July, the European Medicines Agency (EMA) issued several positive opinions recommending the approval of new agents for anticancer indications in Europe. Durvalumab, First Immunotherapy for Locally Advanced NSCLC. The immune checkpoint inhibitor durvalumab (Imfinzi®, AstraZeneca) received a positive opinion for treatment of PD-L1-positive (>1%) patients with locally advanced unresectable non-small cell lung cancer […]

Read More

Multigene Panel Testing Identifies Women With Elevated Risk for TNBC

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer associated with more advanced disease at diagnosis and fewer effective treatment options than other forms of breast cancer. While BRCA1 and BRCA2 mutations are known to be associated with an increased risk of TNBC, little is known about other genes that may predispose […]

Read More

Resistance Mechanisms to Osimertinib in Advanced T790M-Positive NSCLC

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is currently used to treat patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC), including those with acquired resistance to prior TKI therapy through development of the T790M resistance mutation. In patients with T790M mutations, osimertinib is associated with a high response rate and […]

Read More

New FDA-Approved Cancer Treatments in July

• Nivolumab and Ipilimumab Combo Approved for MSI-High Colorectal Cancer. The United States Food and Drug Administration (FDA) expanded the indication of ipilimumab (Yervoy®, Bristol-Myers Squibb) to include use in combination with nivolumab in patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) who have progressed following treatment with […]

Read More

Modified DCF Chemotherapy Highly Effective in Advanced Anal Cancer

Although anal squamous cell carcinoma (ASCC) is a rare disease, incidence of this malignancy is gradually increasing in association with human papillomavirus (HPV) infection. While patients with early stage disease can be treated with surgery, chemotherapy, and radiation, about 35% are diagnosed at a metastatic stage or with recurrent disease after initial chemoradiotherapy. Current treatment […]

Read More

T-DM1 Active in HER2-Mutated Lung Cancer

Human epidermal growth factor receptor 2 (HER2) gene mutations have been detected in a range of cancers, including in approximately 2% of patients with lung adenocarcinoma. HER2 mutations are typically not associated with HER2 amplification and represent a distinct subgroup of HER2-activated lung cancer that may be missed by standard analyses of HER2 positivity based […]

Read More